Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Akoya Biosciences, Inc. (AKYA) had Revenue of $16.64M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$16.64M
Net Income	$-15.65M
Cost of Goods Sold	$6.77M
Gross Profit	$9.87M
Operating Expenses	$30.05M
Operating Income	$-13.41M
Non-Operating Income/Expense	$-2.19M
Pre-Tax Income	$-15.60M
Normalized Pre-Tax Income	$-15.60M
Income after Taxes	$-15.65M
Income from Continuous Operations	$-15.65M
Consolidated Net Income/Loss	$-15.65M
Normalized Income after Taxes	$-15.65M
EBIT	$-13.41M
EBITDA	$-11.61M
Weighted-Average Shares Outstanding (Basic)	49.66M
Weighted-Average Shares Outstanding (Diluted)	49.66M
Earnings per Share (EPS) (Basic)	$-0.32
Earnings per Share (EPS) (Diluted)	$-0.32
Balance Sheet Financials
Current Assets	$66.21M
Property, Plant, and Equipment	$6.92M
Long-Term Assets	$46.44M
Total Assets	$112.65M
Current Liabilities	$108.08M
Long-Term Debt	$0.62M
Long-Term Liabilities	$10.46M
Total Liabilities	$118.54M
Common Equity	$-5.89M
Tangible Shareholders Equity	$-38.00M
Shareholders Equity	$-5.89M
Common Shares Outstanding	49.84M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-7.21M
Cash Flow from Investing Activities	$16.04M
Cash Flow from Financial Activities	$-0.25M
Beginning Cash	$12.46M
End Cash	$21.05M
Increase/Decrease in Cash	$8.58M
Stock-Based Compensation	$2.25M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.61
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.12
Debt to Equity Ratio	-13.18
Gross Margin	59.32%
Operating Margin	-80.61%
EBIT Margin	-80.61%
EBITDA Margin	--
Pre-Tax Profit Margin	-93.78%
Profit Margin	-94.07%
Free Cash Flow	$-7.42M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.30
Receiveable Turnover	1.42
Days Sales in Receivables	63.51
Return on Equity	265.78%
Return on Tangible Equity	41.19%
Return on Assets	-13.89%
Return on Investments	296.83%
Book Value Per Share	$-0.12
Free Cash Flow per Share	$-0.15
Operating Cash Flow per Share	$-0.15

Data from Zacks Investment Research, Inc.